This company has been acquired
Pardes Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Pardes Biosciences has a total shareholder equity of $155.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $157.3M and $1.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$153.20m |
Equity | US$155.39m |
Total liabilities | US$1.93m |
Total assets | US$157.31m |
Recent financial health updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Financial Position Analysis
Short Term Liabilities: PRDS's short term assets ($157.3M) exceed its short term liabilities ($1.9M).
Long Term Liabilities: PRDS has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: PRDS is debt free.
Reducing Debt: PRDS has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRDS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PRDS has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 75.6% each year.